|
| Disease and treatment (number of cases) | Response | Reference |
|
| Uterine fibroid | | |
HIFU (72)
Myomectomy (74) | 87.5% versus 94.6% (P = 0.1282) | [10] |
HIFU (49)
Mifepristone (53) | Tumor shrinkage
95.9% versus 90.6% (P = 0.2770)
Symptom relief
93.9% versus 96.2% (P = 0.5824) | [11] |
Mifepristone (20)
HIFU (20)
HIFU + mifepristone (20) | 85.0% versus 90.0% versus 95.0% (P = 0.5606) | [12] |
|
| Ectopic pregnancy | | |
HIFU (20)
Mifepristone + methotrexate (20) | 80.0% versus 85.0% (P = 0.6769)
| [13] |
|
| Chyluria | | |
HIFU (25)
Lymphatic disconnection (30) | 84.0% versus 83.3% (P = 0.9469)
Relapse
14.3% versus 16.0% (P = 0.8717) | [14] |
|
| Liver cancer | | |
HIFU (20)
Radio frequency (20) | 3-, 6-, 9-, and 12-month survival
80.0%, 61.1%, 42.9%, and 33.3% versus
85.0%, 58.8%, 46.7%, and 36.4%
(P = 0.6769, 1.00, 1.00, 1.00) | [15] |
HIFU (30)
TACE (30) | 0.5-, 1-, and 2-year survival
83.3%, 63.3%, and 40.0% versus
66.7%, 43.3%, and 23.3%
(P = 0.1331, 0.1192, 0.1634) | [16] |
HIFU (40)
γ-knife (38) | Early response
20.0% versus 39.5% (P = 0.0580)
PVTT
52.5% versus 47.4% (P = 0.6504)
MST
10 versus 11 months* (NS) | [17] |
|
| Pancreas cancer | | |
HIFU (20)
Chemotherapy (20) | Early response
50.0% versus 30.0% (P = 0.1949)
6-month survival
70.0% versus 50.0% (P = 0.1949) | [18] |
HIFU + 3DCRT (22)
3DCRT (29)
HIFU (22) | Early response
63.6% versus 44.8% versus 40.9% (P = 0.2611)
0.5-, 1-, and 2-year survival
95.5%, 59.1%, and 50.0% versus
93.1%, 41.4%, and 24.1% versus
95.5%, 40.9%, and 22.7%
(P = 0.9127, 0.3704, 0.0891)
MST
17.6 versus 12.4 versus 12.3 months | [19] |
|
| Prostate cancer | | |
HIFU + emasculation (21)
Emasculation (19) | 5-year survival
83.3% versus 66.7% (P = 0.4430)
Bone metastasis
27.8% versus 50.0% (P = 0.3053) | [20] |
|
